GlassScriptPhysician profile
Alexa Towery
NPI 1679285175
$3,244.42
in general payments reported to CMS, 2019-2025
37 companies · $2,035 in 2025
The $2,035 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.35 · 2023: $382 · 2024: $810 · 2025: $2,035.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,227.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $432.44 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $356.91 | 2023-2025 | |
| Pfizer INC. | $267.67 | 2023-2025 | |
| Eisai INC. | $184.81 | 2025 | |
| Sk Life Science, INC. | $180.87 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $179.97 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Neurocrine Biosciences, INC. | $164.97 | 2025 | |
| Lundbeck LLC | $127.80 | 2025 | Vyepti |
| Vanda Pharmaceuticals INC. | $127.42 | 2025 | Ponvory |
| Bayer Healthcare Pharmaceuticals INC. | $109.47 | 2023-2025 | |
| Novo Nordisk INC | $99.09 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $98.88 | 2024-2025 | |
| Cycle Pharmaceuticals INC | $95.98 | 2025 | Bafiertam, Tascenso Odt |
| Axsome Therapeutics, INC. | $73.18 | 2023-2024 | Auvelity |
| Argenx US, INC. | $66.65 | 2025 | Vyvgart Hytrulo, Vyvgart |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexa Towery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.